CARMA is a multi-centre, cross-sectional study of children with perinatally acquired HIV-1 on sustained suppressive antiretroviral therapy started before 2 years of age. The primary objective is to identify the factors that influence the establishment of a low total HIV DNA in children and adolescents perinatally infected with HIV-1.

The enrollment target is 40 children and the study have been performed at 6 European investigational sites in Italy, Spain and the United Kingdom.

Fondazione Penta Onlus is the sponsor of the trial.